AbbVie (NYSE: ABBV) reported Q2 EPS of $2.65, $0.05 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.02 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $10.71-$10.91, versus the consensus of $10.90.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

Earnings Guidance

Abbvie (ABBV) PT Raised to $200 at Goldman SachsJuly 26, 2024 5:53 AM William Blair Reiterates Outperform Rating on Abbvie (ABBV)July 26, 2024 5:37 AM Abbvie (ABBV) PT Raised to $210 at Truist SecuritiesJuly 25, 2024 4:12 PM Abbvie (ABBV) PT Raised to $210 at JPMorganJuly 25, 2024 3:56 PM AbbVie hikes full-year earnings guidance as Humira sales top estimatesJuly 25, 2024 7:56 AM